ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid Tumors

Jedd D. Wolchok, MD, PhD
Published Online:1:57 PM, Wed May 24, 2017

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.